Serono Says New Rebif Formulation Could Increase Tolerability
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm files the human serum albumin-free and fetal bovine serum-free interferon beta-1a in the U.S. and the EU.
You may also be interested in...
Rebif’s New Formulation Delayed By FDA
Merck Serono says it is in discussions with FDA to answer outstanding questions over the new formulation of the multiple sclerosis drug.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.